Project Grant R01AG095009
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $6.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $9,781,240 Project Grant to the Institute For Molecular Medicine Inc. in California. The grant funds a multicenter Phase 1 clinical trial to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals at risk of Alzheimer's disease (preclinical stage). The project aims to develop an innovative immunotherapy approach for...
- This $6,925,230 Project Grant award from the National Institutes of Health (NIH) National Institute on Aging (CFDA 93.866 - Aging Research) will support a research project at The Trustees of Columbia University in the City of New York to develop a "Multi-Organ Chart of Personalized Susceptibility to Alzheimer's Disease and Aging." The overarching goal is to use large-scale multi-omics, multi-organ biomedical data, advanced artificial intelligence/machine learning, and computational...
- The National Institute on Aging (NIA), through its Aging Research Federal Grant Program (CFDA 93.866), awarded a $498,709 project grant to Epoch Biotech, LLC on August 20, 2025. The funding supports preclinical research on an ApoE-targeted antibody for treating Alzheimer's disease (AD). The project aims to modulate the interaction between apolipoprotein E (ApoE) and glycosaminoglycans (GAGs) using a therapeutic humanized antibody. The research builds on the discovery of a protective ApoE3...
- This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides funding of $1,480,275 to the University of Southern California to develop new lead compounds that inhibit the calcium-dependent phospholipase A2 (cPLA2) enzyme, which is a promising therapeutic target for treating neuroinflammation in Alzheimer's disease. The team will establish a comprehensive structure-activity relationship for their lead and backup compounds, and develop an in vivo...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This federal Project Grant award for $831,583 was provided by the National Institute on Aging (CFDA 93.866 Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Characterizing Microvascular Impairment in Adults with Elevated Genetic Risk for Alzheimer's Disease." The project aims to elucidate the physiological mechanisms by which the APOE-E4 genetic risk factor contributes to microvascular impairment,...
- The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $167,940 project grant to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease. The project, awarded on August 15, 2025, aims to (1) determine if the MEF2 transcription factors mediate survival of specific neuronal subtypes vulnerable to Alzheimer's pathology, (2) assess whether...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,400 to Nova Southeastern University to conduct research comparing the therapeutic potential of three compounds - tirzepatide, retatrutide, and crocetin - in mitigating Alzheimer's-like pathology in a mouse model of comorbid Alzheimer's disease and obesity/prediabetes. The 3-year study, running from December 2024 to November 2027, will assess the impact of these interventions on...